Recent Updates
Recently added Catalysts

Lopressor HCT 100

Phase 1

Healthy | Small molecule | Other |Viatris Inc.|Last Updated: Apr 24, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment64

FDA Designations

No designations recorded

Clinical trial landscape

Lopressor HCT 100 · 2 trials · 1 indication

Phase 1 2
NCT00649233Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mgHealthy
COMPLETED32 Analytics
NCT00649688Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mgHealthy
COMPLETED32 Analytics
PHASE1COMPLETED
Food Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg to Lopressor HCT® Tablets 100/50 mg
HealthyUnlock trial analytics
PHASE1COMPLETED
Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence
within 30 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTALMetoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg
2ACTIVE_COMPARATORLopressor HCT® Tablets 100/50 mg

Interventions

NameTypeDescription
Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mgDRUG100/50mg, single dose fed
Lopressor HCT® Tablets 100/50 mgDRUG100/50mg, single dose fed
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum Beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Lopressor HCT 100

What is Lopressor HCT 100 used for?

Lopressor HCT 100 is a combination tablet being studied in healthy volunteers. It contains metoprolol tartrate and hydrochlorothiazide, and is being evaluated in Phase 1 bioavailability studies comparing the generic formulation to the reference product. The studies are conducted in the United States with healthy adult participants.

Who makes Lopressor HCT 100?

Lopressor HCT 100 is developed by Viatris Inc., which trades under the ticker VTRS. The company is conducting Phase 1 clinical trials to evaluate the pharmacokinetics of the combination tablet in healthy volunteers.

What phase is Lopressor HCT 100 in?

Lopressor HCT 100 is in Phase 1 clinical development. Two Phase 1 studies have been completed, both involving healthy volunteers. The drug is investigational and has not been approved for marketing based on the available clinical trial data.

What clinical trials is Lopressor HCT 100 in?

Lopressor HCT 100 has been studied in two completed Phase 1 trials: NCT00649233, a food study comparing metoprolol tartrate/hydrochlorothiazide 100/50 mg tablets to Lopressor HCT 100/50 mg tablets, and NCT00649688, a fasting study with the same comparison. Each trial enrolled 32 healthy participants in the United States.

Is Lopressor HCT 100 the same as metoprolol tartrate/hydrochlorothiazide?

Lopressor HCT 100 is a brand-name combination tablet containing metoprolol tartrate and hydrochlorothiazide. The clinical trials compare the generic metoprolol tartrate/hydrochlorothiazide 100/50 mg tablets to Lopressor HCT 100/50 mg tablets to assess bioequivalence.